FDA Warns Matrixx On Combination Supplement/Drug Products
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives’ troubled history with FDA continues with a warning two of its products are unapproved new drugs because they combine supplements with OTC drugs.
You may also be interested in...
FDA Regulation Of Homeopathics Does Not Pre-empt Damages Claims – Court
A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.
Homeopathics Reap Rewards From Sowing Fields For Success – Hyland's CEO
Hyland's and other homeopathic remedy firms did not expect quality control problems at the most well known OTC drug to drive growth for the homeopathic sector.
FDA Underlines Disapproval Of Drug-Supplement Combos In Letter To P&G
FDA notes once again that combination OTC drug and dietary supplement products are unapproved new drugs with a warning letter sent Oct. 29 to Procter & Gamble about Vicks DayQuil Plus Vitamin C and VicksNyQuil Plus Vitamin C